{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:08:56Z","timestamp":1776384536199,"version":"3.51.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction and objectives<\/jats:title><jats:p>Mitochondrial pyruvate carrier (MPC) mediates the entry of pyruvate into mitochondria, determining whether pyruvate is incorporated into the Krebs cycle or metabolized in the cytosol. In heart failure (HF), a large amount of pyruvate is metabolized to lactate in the cytosol rather than being oxidized inside the mitochondria. Thus, MPC activity or expression might play a key role in the fate of pyruvate during HF. The purpose of this work was to study the levels of the two subunits of this carrier, named MPC1 and MPC2, in human hearts with HF of different etiologies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Protein and mRNA expression analyses were conducted in cardiac tissues from three donor groups: patients with HF with reduced ejection fraction (HFrEF) with ischemic cardiomyopathy (ICM) or idiopathic dilated cardiomyopathy (IDC), and donors without cardiac pathology (Control). MPC2 plasma levels were determined by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant reductions in the levels of MPC1, MPC2, and Sirtuin 3 (SIRT3) were observed in ICM patients compared with the levels in the Control group. However, no statistically significant differences were revealed in the analysis of MPC1 and MPC2 gene expression among the groups. Interestingly, Pyruvate dehydrogenase complex (PDH) subunits expression were increased in the ICM patients. In the case of IDC patients, a significant decrease in MPC1 was observed only when compared with the Control group. Notably, plasma MPC2 levels were found to be elevated in both disease groups compared with that in the Control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Decreases in MPC1 and\/or MPC2 levels were detected in the cardiac tissues of HFrEF patients, with ischemic or idiopatic origen, indicating a potential reduction in mitochondrial pyruvate uptake in the heart, which could be linked to unfavorable clinical features.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1349417","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:38:07Z","timestamp":1709872687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin"],"prefix":"10.3389","volume":"11","author":[{"given":"Paula","family":"Lopez-Vazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Fernandez-Caggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Couto-Mallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulaika","family":"Grille-Cancela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Blanco-Canosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Paniagua-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Enriquez-Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Vazquez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Crespo-Leiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10741-007-9071-9","article-title":"Intracellular devastation in heart failure","volume":"13","author":"Del Monte","year":"2008","journal-title":"Heart Fail Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2143\/AC.64.4.2041617","article-title":"Proteomic analysis identifies mitochondrial metabolic enzymes as major discriminators between different stages of the failing human myocardium","volume":"64","author":"Urbonavicius","year":"2009","journal-title":"Acta Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/CIRCRESAHA.112.265660","article-title":"Mitochondria as a drug target in ischemic heart disease and cardiomyopathy","volume":"111","author":"Walters","year":"2012","journal-title":"Circ Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbalip.2009.09.014","article-title":"Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle","volume":"1801","author":"Zhang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1006\/jmcc.1998.0804","article-title":"Glucose utilization and glycogen turnover are acelerated in hypertrophied rat hearts during severe low-flow ischemia","volume":"31","author":"Wambolt","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/cvr\/cvr052","article-title":"Metabolic remodelling in human heart failure","volume":"90","author":"Tuunanen","year":"2011","journal-title":"Cardiovasc Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00018-013-1539-2","article-title":"Regulation of pyruvate metabolism and human disease","volume":"71","author":"Gray","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0008-6363(98)00300-9","article-title":"Mitochondrial metabolism of pyruvate is required for its enhancement of cardiac function and energetics","volume":"42","author":"Mallet","year":"1999","journal-title":"Cardiovasc Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1218530","article-title":"Identification and functional expression of the mitochondrial pyruvate carrier","volume":"337","author":"Herzig","year":"2012","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.1218099","article-title":"A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans","volume":"337","author":"Bricker","year":"2012","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.bbamcr.2016.01.017","article-title":"The mitochondrial pyruvate carrier in health and disease: to carry or not to carry?","volume":"1863","author":"Bender","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3171\/2017.9.JNS172036","article-title":"Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma","volume":"130","author":"Karsy","year":"2018","journal-title":"J Neurosurg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1186\/s12885-016-2941-6","article-title":"MPC1 And MPC2 expressions are associated with favorable clinical outcomes in prostate cancer","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1074\/jbc.M113.521666","article-title":"Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion","volume":"289","author":"Patterson","year":"2014","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/STROKEAHA.111.620088","article-title":"Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway","volume":"43","author":"Ryou","year":"2012","journal-title":"Stroke"},{"key":"B16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1074\/mcp.M115.051862","article-title":"Analysis of mitochondrial proteins in the surviving myocardium after ischemia identifies mitochondrial pyruvate carrier expression as possible mediator of tissue viability","volume":"15","author":"Fern\u00e1ndez-Caggiano","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s42255-020-00276-5","article-title":"Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy","volume":"21","author":"Fernandez-Caggiano","year":"2020","journal-title":"Nat Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s42255-020-00288-1","article-title":"Mitochondrial pyruvate carriers are required for myocardial stress adaptation","volume":"2","author":"Zhang","year":"2020","journal-title":"Nat Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s42255-020-00296-1","article-title":"Nutritional modulation of heart failure in mitochondrial pyruvate carrier- deficient mice","volume":"2","author":"McCommis","year":"2020","journal-title":"Nat Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4532592","DOI":"10.1155\/2019\/4532592","article-title":"Adaptations in protein expression and regulated activity of pyruvate dehydrogenase multienzyme Complex in human systolic heart failure","volume":"2019","author":"Sheeran","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","article-title":"The pyruvate- lactate axis modulates cardiac hypertrophy and heart failure","volume":"33","author":"Cluntun","year":"2021","journal-title":"Cell Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.str.2019.04.009","article-title":"Structural and functional analyses of the human PDH complex suggest a \u201cdivision-of-labor\u201d mechanism by local E1 and E3 clusters","volume":"27","author":"Prajapati","year":"2019","journal-title":"Structure"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/01.cir.91.7.2071","article-title":"Pyruvate dehydrogenase influences postischemic heart function","volume":"91","author":"Lewandowski","year":"1995","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0185046","DOI":"10.1371\/journal.pone.0185046","article-title":"Enhanced pyruvate dehydrogenase activity improves cardiac outcomes in a murine model of cardiac arrest","volume":"12","author":"Piao","year":"2017","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7293861","DOI":"10.1155\/2018\/7293861","article-title":"SIRT3: a new regulator of cardiovascular diseases","volume":"2018","author":"Sun","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbrc.2015.11.036","article-title":"Sirt3 binds to and deacetylates mitochondrial pyruvate carrier 1 to enhance its activity","volume":"468","author":"Liang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1074\/jbc.M116.753509","article-title":"Decreased mitochondrial pyruvate transport activity in the diabetic heart: role of mitochondrial pyruvate carrier 2 (MPC2) acetylation","volume":"292","author":"Vadvalkar","year":"2017","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41418-020-00729-0","article-title":"Heart failure-emerging roles for the mitochondrial pyruvate carrier","volume":"28","author":"Fernandez-Caggiano","year":"2021","journal-title":"Cell Death Differ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 European Society of cardioLogy (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). with the special contribution of the heart failure association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115405","DOI":"10.1016\/j.bcp.2022.115405","article-title":"Targeting mitochondrial impairment for the treatment of cardiovascular diseases: from hypertension to ischemia-reperfusion injury, searching for new pharmacological targets","volume":"208","author":"Todisco","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1111\/jcmm.14330","article-title":"The role of post-translational modifications in cardiac hypertrophy","volume":"23","author":"Yan","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.bbamcr.2012.08.014","article-title":"Targeting mitochondrial oxidative metabolism as an approach to treat heart failure","volume":"1863","author":"Fillmore","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0735-1097(02)01967-8","article-title":"Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy","volume":"40","author":"D\u00e1vila-Rom\u00e1n","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.119.045401","article-title":"Transcriptional and cellular diversity of the human heart","volume":"142","author":"Tucker","year":"2020","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1161\/CIRCRESAHA.116.308139","article-title":"Recounting cardiac cellular composition","volume":"118","author":"Zhou","year":"2016","journal-title":"Circ Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1349417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:38:09Z","timestamp":1709872689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1349417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2024.1349417"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1349417","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"article-number":"1349417"}}